Amgen chief Bradway nabs a rare disease player in $4B buyout as the M&A tempo accelerates

Amgen CEO Bob Bradway is bellying up to the M&A table today, scooping up the newly anointed commercial biotech ChemoCentryx $CCXI and its recently approved rare disease drug for $3.7 billion out of the cash stockpile. The deal comes in at $52...

Click to view original post